Journal of Gastrointestinal Surgery

, Volume 19, Issue 7, pp 1271–1280 | Cite as

Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis

  • Wei Liu
  • Jian-Guo Zhou
  • Yi Sun
  • Lei Zhang
  • Bao-Cai Xing
Original Article



Hepatic resection has been increasingly performed in patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), but the current evidence supporting its efficacy remains controversial. The aim of this systematic review was to investigate the long-term survival and safety of hepatic resection compared to transarterial chemoembolization (TACE) alone for BCLC stage B HCC.


Eligible trials that compared hepatic resection with TACE alone for intermediate HCC were identified from the Embase, PubMed, Web of Science, and Cochrane databases. The study outcomes included overall survival (OS) rate and treatment-related complication rate. Hazard ratios (HRs) with a 95 % confidence interval were used to measure the pooled effect according to a random-effects or fixed-effects model, depending on the heterogeneity among the included studies. The heterogeneity among these trials statistically was evaluated using the χ2 and I 2 tests. Sensitivity analyses were also performed.


A total of 9 studies containing 4958 patients were included. The comparison between hepatic resection and TACE revealed a pooled HR for 3-year OS of 0.403 (95 % CI 0.364–0.446, p = 0.000; I 2 = 0 %, p = 0.643) and a pooled HR for 5-year OS of 0.433 (95 % CI 0.394–0.475, p = 0.000; I 2 = 0 %, p = 0.468). An AFP level >400 ng/ml and being HBV-positive were factors significantly correlated with overall survival. For treatment-related complications, the overall odds ratio (OR) for hepatic resection versus TACE was 0.990 (95 % CI 0.934–1.049; p = 0.728; I 2 = 64.5 %, p = 0.060).


Hepatic resection likely improved overall survival compared with TACE alone in BCLC stage B HCC patients, but did not increase the incidence of treatment-related complications. An AFP level >400 ng/ml and HBV positivity were significantly correlated with poor OS.


Hepatocellular carcinoma TACE BCLC Resection 

Supplementary material

11605_2015_2811_MOESM1_ESM.tif (39 kb)
Fig. S2a Forrest plot summarizing the meta-analysis of gender (female vs. male) (TIF 39.2 kb)
11605_2015_2811_MOESM2_ESM.tif (36 kb)
Fig. S2b Forrest plot summarizing the meta-analysis of age (>50 vs. ≤50 years) (TIF 35.7 kb)
11605_2015_2811_MOESM3_ESM.tif (36 kb)
Fig. S2c Forrest plot summarizing the meta-analysis of Child-Pugh grade (B vs.A) (TIF 36.4 kb)
11605_2015_2811_MOESM4_ESM.tif (36 kb)
Fig. S2d Forrest plot summarizing the meta-analysis of tumor number (>1 vs.1) (TIF 35.9 kb)
11605_2015_2811_MOESM5_ESM.tif (740 kb)
Fig. S2e(1) Forrest plot summarizing the meta-analysis of tumor size (>5 vs.≤5 cm) (TIF 739 kb)
11605_2015_2811_MOESM6_ESM.tif (35 kb)
Fig. S2e(2) Forrest plot summarizing the meta-analysis of tumor size (>10 vs. ≤10 cm) (TIF 34.5 kb)
11605_2015_2811_MOESM7_ESM.tif (37 kb)
Fig. S2f Forrest plot summarizing the meta-analysis of AFP (>400 vs. ≤400 ng/ml) (TIF 37.0 kb)
11605_2015_2811_MOESM8_ESM.tif (36 kb)
Fig. S2g Forrest plot summarizing the meta-analysis of HBV (+vs. −) (TIF 36.2 kb)


  1. 1.
    Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Yuen M F, Hou J L, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region[J]. J Gastroenterol Hepatol,2009,24(3):346–353.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag H B. Hepatocellular carcinoma[J]. N Engl J Med,2011,365(12):1118–1127.PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet J M, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis,1999,19(3):329–338.PubMedCrossRefGoogle Scholar
  5. 5.
    Rhim H, Lim H K, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma[J]. World J Gastrointest Surg,2010,2(4):128–136.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020–1022.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system[J]. J Hepatol,2006,44(4):723–731.PubMedCrossRefGoogle Scholar
  8. 8.
    Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients[J]. J Gastrointest Surg,2009,13(7):1313–1320.PubMedCrossRefGoogle Scholar
  9. 9.
    Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma[J]. Gastroenterology,2008,134(7):1908–1916.PubMedCrossRefGoogle Scholar
  10. 10.
    Sb W G. Newcastle-Ottawa Scale (NOS) for assessing the quality if non-randomized studies in meta-analyses[Z]. 2009.Google Scholar
  11. 11.
    Guyatt G H, Oxman A D, Vist G E, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ,2008,336(7650):924–926.Google Scholar
  12. 12.
    Tierney J F, Stewart L A, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials,2007,8:16.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Dersimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials,1986,7(3):177–188.PubMedCrossRefGoogle Scholar
  14. 14.
    Heng-Jun G, Yao-Jun Z, Min-Shan C, et al. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma[J]. Liver Int,2014,34(4):612–620.PubMedCrossRefGoogle Scholar
  15. 15.
    Ho M C, Huang G T, Tsang Y M, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas[J]. Ann Surg Oncol,2009,16(4):848–855.PubMedCrossRefGoogle Scholar
  16. 16.
    Jin Y J, Lee J W, Choi Y J, et al. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A[J]. J Gastrointest Surg,2014,18(3):555–561.PubMedCrossRefGoogle Scholar
  17. 17.
    Jianyong L, Lunan Y, Wentao W, et al. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?[J]. Medicine (Baltimore),2014,93(26):e180.CrossRefGoogle Scholar
  18. 18.
    Lin C T, Hsu K F, Chen T W, et al. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?[J]. World J Surg,2010,34(9):2155–2161.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang J H, Changchien C S, Hu T H, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients[J]. Eur J Cancer,2008,44(7):1000–1006.PubMedCrossRefGoogle Scholar
  20. 20.
    Yin L, Li H, Li A J, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol,2014,61(1):82–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhong J H, Xiang B D, Gong W F, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization[J]. PLoS One,2013,8(7):e68193.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Zhong J H, Li H, Xiao N, et al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension[J]. PLoS One,2014,9(9):e108755.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908–943.Google Scholar
  24. 24.
    Llovet J M, Real M I, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet,2002,359(9319):1734–1739.PubMedCrossRefGoogle Scholar
  25. 25.
    Lo C M, Ngan H, Tso W K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology,2002,35(5):1164–1171.PubMedCrossRefGoogle Scholar
  26. 26.
    Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology,2003,37(2):429–442.PubMedCrossRefGoogle Scholar
  27. 27.
    Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design[J]. J Hepatol,2012,56(6):1330–1335.PubMedCrossRefGoogle Scholar
  28. 28.
    Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol,2010,194(3):830–837.PubMedCrossRefGoogle Scholar
  29. 29.
    Roayaie S. TACE vs. surgical resection for BCLC stage B HCC[J]. J Hepatol,2014,61(1):3–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Lencioni R, Chen X P, Dagher L, et al. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?[J]. Oncologist,2010,15 Suppl 4:42–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded?[J]. Dig Liver Dis,2010,42 Suppl 3:S258-S263.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim J H, Won H J, Shin Y M, et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone[J]. Ann Surg Oncol,2011,18(6):1624–1629.PubMedCrossRefGoogle Scholar
  33. 33.
    Forner A, Llovet J M, Bruix J. Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245–1255.PubMedCrossRefGoogle Scholar
  34. 34.
    Kudo M, Han K H, Kokudo N, et al. Liver Cancer Working Group report[J]. Jpn J Clin Oncol,2010,40 Suppl 1:i19-i27.PubMedCrossRefGoogle Scholar
  35. 35.
    Chan S L, Mo F K, Johnson P J, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population[J]. J Gastroenterol Hepatol,2011,26(2):340–347.PubMedCrossRefGoogle Scholar
  36. 36.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis[J]. Lancet,1995,346(8982):1051–1055.PubMedCrossRefGoogle Scholar
  37. 37.
    Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years[J]. Arch Surg,2003,138(11):1198–1206, 1206.PubMedCrossRefGoogle Scholar
  38. 38.
    Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol,2007,30(1):6–25.PubMedCrossRefGoogle Scholar
  39. 39.
    Poon R T, Fan S T, Lo C M, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database[J]. Ann Surg,2004,240(4):698–708, 708–710.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Jarnagin W R, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade[J]. Ann Surg,2002,236(4):397–406, 406–407.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Inoue Y, Hasegawa K, Ishizawa T, et al. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma?[J]. Surgery,2009,145(1):9–19.Google Scholar
  42. 42.
    Zhang Z M, Guo J X, Zhang Z C, et al. Therapeutic options for intermediate-advanced hepatocellular carcinoma[J]. World J Gastroenterol,2011,17(13):1685–1689.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Bolondi L, Burroughs A, Dufour J F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis,2012,32(4):348–359.PubMedGoogle Scholar
  44. 44.
    Hsu C Y, Hsia C Y, Huang Y H, et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis[J]. Ann Surg Oncol,2012,19(3):842–849.PubMedCrossRefGoogle Scholar
  45. 45.
    Liu L, Miao R, Yang H, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China[J]. Am J Surg,2012,203(6):741–750.PubMedCrossRefGoogle Scholar
  46. 46.
    Chevret S, Trinchet J C, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire[J]. J Hepatol,1999,31(1):133–141.PubMedCrossRefGoogle Scholar
  47. 47.
    Chan S L, Mo F K, Johnson P J, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy[J]. J Clin Oncol,2009,27(3):446–452.PubMedCrossRefGoogle Scholar
  48. 48.
    Naugler W E, Alsina A E, Frenette C T, et al. Building the Multidisciplinary Team for Management of Patients With Hepatocellular Carcinoma[J]. Clin Gastroenterol Hepatol,2014.Google Scholar
  49. 49.
    Zhong J H, Li L Q. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis[J]. Hepatol Res,2010,40(10):943–953.PubMedCrossRefGoogle Scholar
  50. 50.
    Jiang S, Liu Y, Wang L, et al. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma[J]. World J Surg Oncol,2013,11:240.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Chen X P, Hu D Y, Zhang Z W, et al. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma[J]. Dig Surg,2007,24(3):208–213.PubMedCrossRefGoogle Scholar
  52. 52.
    Gerunda G E, Neri D, Merenda R, et al. Role of transarterial chemoembolization before liver resection for hepatocarcinoma[J]. Liver Transpl,2000,6(5):619–626.PubMedCrossRefGoogle Scholar
  53. 53.
    Shamliyan T A, Macdonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference[J]. Ann Intern Med,2009,150(2):111–124.PubMedCrossRefGoogle Scholar
  54. 54.
    Lo C M, Liu C L, Chan S C, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J]. Ann Surg,2007,245(6):831–842.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis[J]. Hepatology,2006,44(6):1543–1554.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2015

Authors and Affiliations

  • Wei Liu
    • 1
  • Jian-Guo Zhou
    • 2
  • Yi Sun
    • 1
  • Lei Zhang
    • 1
  • Bao-Cai Xing
    • 1
  1. 1.Hepatopancreatobiliary Surgery Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of EducationPeking University School of Oncology, Beijing Cancer Hospital and InstituteBeijingPeople’s Republic of China
  2. 2.Department of Oncology, Affiliated Hospital of Zunyi Medical UniversityZunyi Medical UniversityZunyiPeople’s Republic of China

Personalised recommendations